Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20

Journal Article · · Journal of Medicinal Chemistry
 [1];  [2];  [1];  [3];  [3];  [1]
  1. Georgia State Univ., Atlanta, GA (United States)
  2. National Inst. of Health (NIH), Bethesda, MD (United States)
  3. Purdue Univ., West Lafayette, IN (United States)
An extremely drug resistant mutant of HIV-1 protease (PR) bearing 20 mutations (PR20) has been studied with two potent antiviral investigational inhibitors. GRL-5010A and GRL-4410A were designed to introduce hydrogen bond interactions with the flexible flaps of the PR by incorporating gem-difluorines and alkoxy, respectively, at the C4 position of the bis-THF of darunavir. PR20 provides an excellent model for high level resistance, since clinical inhibitors are >1000-fold less active on PR20 than on wild-type enzyme. GRL-5010A and GRL-4410A show inhibition constants of 4.3 ± 7.0 and 1.7 ± 1.8 nM, respectively, for PR20, compared to the binding affinity of 41 ± 1 nM measured for darunavir. Crystal structures of PR20 in complexes with the two inhibitors confirmed the new hydrogen bond interactions with Gly 48 in the flap of the enzyme. In conclusion, the two new compounds are more effective than darunavir in inhibiting mature PR20 and show promise for further development of antiviral agents targeting highly resistant PR mutants.
Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States)
Sponsoring Organization:
National Inst. of Health
OSTI ID:
1213713
Journal Information:
Journal of Medicinal Chemistry, Journal Name: Journal of Medicinal Chemistry Journal Issue: 12 Vol. 58; ISSN 0022-2623
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (39)

Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors journal September 2010
Design of gem -Difluoro- bis -Tetrahydrofuran as P2 Ligand for HIV-1 Protease Inhibitors to Improve Brain Penetration: Synthesis, X-ray Studies, and Biological Evaluation journal October 2014
Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: Relevance to drug resistance: Characterization of Group N HIV-1 Protease journal September 2010
Combined use of computational chemistry, NMR screening, and X-ray crystallography for identification and characterization of fluorophilic protein environments journal November 2010
On the size of the active site in proteases. I. Papain journal April 1967
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997
HIV-I protease: Maturation, enzyme specificity, and drug resistance book January 2000
HIV‐1 Protease: Structure, Dynamics, and Inhibition book June 2007
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study journal October 2011
Neurological complications of HIV infection journal September 2005
Mechanism of Drug Resistance Revealed by the Crystal Structure of the Unliganded HIV-1 Protease with F53L Mutation journal May 2006
Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus journal August 2005
Halogen Bonding Based Recognition Processes:  A World Parallel to Hydrogen Bonding journal May 2005
Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance journal January 2008
HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural Rearrangements journal March 2012
Fluorine Bonding — How Does It Work In Protein−Ligand Interactions? journal September 2009
Subtype Polymorphisms Among HIV-1 Protease Variants Confer Altered Flap Conformations and Flexibility journal September 2009
Extreme Multidrug Resistant HIV-1 Protease with 20 Mutations Is Resistant to Novel Protease Inhibitors with P1′-Pyrrolidinone or P2-Tris-tetrahydrofuran journal May 2013
Halogen BondingA Novel Interaction for Rational Drug Design? journal May 2009
Design of HIV-1 Protease Inhibitors with Pyrrolidinones and Oxazolidinones as Novel P1′-Ligands To Enhance Backbone-Binding Interactions with Protease: Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies journal May 2009
Design, Synthesis, and X-ray Structure of Substituted Bis-tetrahydrofuran (Bis-THF)-Derived Potent HIV-1 Protease Inhibitors journal January 2011
HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis journal June 2010
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors journal May 2011
Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus–infected patients journal January 2006
Short Communication: Prevalence of HIV-1 Transmitted Drug Resistance in Liberia journal September 2014
Clinical and immunogenetic correlates of abacavir hypersensitivity journal January 2005
HIV Prevention by Oral Preexposure Prophylaxis journal December 2011
Likelihood-enhanced fast rotation functions journal February 2004
Coot model-building tools for molecular graphics journal November 2004
Likelihood-enhanced fast translation functions journal March 2005
High-resolution structure of unbound human immunodeficiency virus 1 subtype C protease: implications of flap dynamics and drug resistance journal June 2008
Refinement of Macromolecular Structures by the Maximum-Likelihood Method journal May 1997
GRL-04810 and GRL-05010, Difluoride-Containing Nonpeptidic HIV-1 Protease Inhibitors (PIs) That Inhibit the Replication of Multi-PI-Resistant HIV-1 In Vitro and Possess Favorable Lipophilicity That May Allow Blood-Brain Barrier Penetration journal September 2013
Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier journal October 2007
Incidence of Transmitted Antiretroviral Drug Resistance in Treatment-Naive HIV-1-Infected Persons in a Large South Central United States Clinic journal January 2014
Halogen Atoms in the Modern Medicinal Chemistry: Hints for the Drug Design journal March 2010
Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review journal January 2012
HIV drug resistance: problems and perspectives journal June 2013
Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights journal August 2009

Similar Records

Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20
Journal Article · Wed Aug 28 20:00:00 EDT 2019 · Biochemical and Biophysical Research Communications · OSTI ID:1572565

HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics
Journal Article · Wed Aug 31 20:00:00 EDT 2022 · Journal of Molecular Graphics and Modelling · OSTI ID:1887649

HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural Rearrangements
Journal Article · Thu Jun 28 00:00:00 EDT 2012 · Biochemistry-US · OSTI ID:1041326